Anebulo Pharmaceuticals

What Anebulo Pharmaceuticals does

Anebulo Pharmaceuticals is a clinical-stage biopharmaceutical company developing selonabant (ANEB-001), a potent small-molecule antagonist of the cannabinoid type 1 (CB1) receptor, for the treatment of acute cannabinoid intoxication (ACI) in adults and unintentional cannabis poisoning in pediatric patients. The company is developing two formulations of the same active ingredient: an orally bioavailable version for adults presenting with ACI, for which a Phase 2 clinical trial has been completed with positive data, and an intravenous (IV) formulation scaled up for pediatric use, for which a Phase 1 single ascending dose study was initiated in September 2025. Anebulo is targeting hospital emergency departments as the primary point of care, particularly for pediatric patients who face serious outcomes including CNS depression, respiratory depression, seizures, and coma from accidental edible cannabis ingestion.

The business is pre-revenue with no marketed products or commercial sales, and revenue would only begin upon regulatory approval of either formulation. As of Q2 FY2026, the company reported a $2.0 million net loss on $2.6 million of operating expenses and $9.0 million in cash reserves. Capital sources to date include a $6.6 million private placement in September 2022, an approximately $15 million financing in December 2024 led by 22NW, LP, and multiple National Institute on Drug Abuse (NIDA) grant tranches totaling roughly $3.8 million directed at the IV pediatric program. The company holds two issued patents covering methods of use of selonabant and composition of matter of the crystalline form, with multiple pending applications covering delivery systems.

In February 2026, Anebulo's board approved voluntary delisting from the Nasdaq Capital Market and deregistration with the SEC, effective February 27, 2026, to eliminate the costs of public reporting. The company had previously announced a self-tender offer in December 2025 to repurchase up to 300,000 shares at $3.50 per share as part of its go-private strategy. Leadership consists of CEO Richie Cunningham, Acting CFO Daniel George, and Founder/Chairman Joseph F. Lawler, operating with a small team of 1-10 employees out of Lakeway, Texas.

Name

Anebulo Pharmaceuticals

Legal name

Anebulo Pharmaceuticals, Inc.

Website

https://anebulo.com

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Anebulo Pharmaceuticals is a clinical-stage biopharmaceutical company developing selonabant, a CB1 receptor antagonist in oral and intravenous formulations for treating acute cannabinoid intoxication and unintentional pediatric cannabis poisoning, with no FDA-approved competing treatments.

Ownership category

akta.pro rank

Product category

Cannabinoid Intoxication Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Cannabinoid intoxication treatment
• CB1 receptor antagonist
• Clinical-stage biopharmaceutical
• Acute cannabis toxicity
• Pediatric poisoning antidote

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Pharmaceutical Product Revenue: As a clinical-stage biopharmaceutical company, Anebulo does not yet have commercial revenue. Its lead product candidate selonabant is in clinical development (Phase 2 completed, Phase 1 SAD study for IV formulation initiated September 2025). Revenue would come from commercialization of drug candidates upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Anebulo Pharmaceuticals is a clinical-stage biopharmaceutical company developing selonabant (ANEB-001), a small-molecule CB1 receptor antagonist, as a treatment for acute cannabinoid intoxication (ACI) and unintentional cannabis poisoning. The candidate is being advanced in two formulations: an oral version for adult ACI (Phase 2 completed) and an intravenous (IV) formulation prioritized for pediatric patients presenting to emergency departments with cannabis-induced toxicity (Phase 1 SAD study initiated September 2025).

Product overview

Anebulo Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics for acute cannabinoid toxicities. The company's lead product candidate is selonabant (ANEB-001), a potent CB1 receptor antagonist available in two formulations: an oral version for treating acute cannabinoid intoxication in adults, and an intravenous (IV) formulation being prioritized for pediatric patients with unintentional cannabis poisoning. The company is focused on addressing the unmet medical need for a specific antidote for cannabis toxicity, particularly given the rising incidence of emergency department visits linked to increased cannabis legalization.

Differentiator

Problem solved

Functional benefit

Products and services

• ANEB-001 (Selonabant) — Oral Formulation Potent, orally bioavailable, small-molecule CB1 receptor antagonist under development as a treatment for acute cannabinoid intoxication (ACI) in adults. Designed to be readily absorbed and to rapidly reverse key symptoms of cannabis intoxication including CNS depression. Completed Phase 2 clinical trial with positive data.
• IV Selonabant (ANEB-001 Intravenous Formulation) Intravenous (parenteral) formulation of selonabant developed specifically for pediatric patients presenting to emergency departments with acute cannabis-induced toxicity. Designed for rapid onset to address serious and life-threatening outcomes such as CNS depression, respiratory depression, seizures, and coma in children who have suffered unintentional cannabis poisoning.

Quantifiable outcome

• Phase 2 clinical trial for oral selonabant (ANEB-001) completed with positive data demonstrating potential as a treatment for acute cannabinoid intoxication.
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators10 records

Recent moves8 records

Expansion highlights4 records

Broad incumbents

• Indivior: Established specialty pharma focused on substance use disorder treatments, most notably opioid use disorder. Comparable to Anebulo in targeting acute substance-related toxicities and addiction indications with prescription pharmaceuticals.
• Axsome Therapeutics: Commercial-stage CNS biopharma with a portfolio of small-molecule therapies for migraine and other neurological indications. Comparable to Anebulo in building a franchise around novel CNS receptor mechanisms.
• Sage Therapeutics: CNS-focused biopharma developing GABA receptor modulators for depression and rare epilepsies. Comparable to Anebulo in pursuing CNS receptor-targeted small molecules for underserved neurological indications.
• Harmony Biosciences: Specialty CNS biopharma commercializing a single-asset franchise for narcolepsy with strong orphan/specialty pricing dynamics. Comparable to Anebulo in being a focused, small commercial-stage CNS company built around a niche receptor-targeting asset.
• Jazz Pharmaceuticals: Specialty biopharma with a CNS and rare-disease commercial franchise including treatments for substance-related and acute neurological indications. Comparable to Anebulo in targeting CNS conditions via specialty sales channels to prescribers.

Emerging players

• BioXcel Therapeutics: Clinical-to-commercial stage biopharma developing novel CNS and immuno-oncology therapies, with a similar small-cap, single-platform specialty pharma profile to Anebulo.
• Aelis Farma: Clinical-stage biotech developing CB1 receptor signaling-specific therapeutics (CB1-SSi) for cannabis-related and other CNS disorders. Directly comparable mechanism-class competitor to Anebulo's CB1 antagonist approach.
• Clearmind Medicine: Clinical-stage biotech developing psychedelic-derived therapeutics for addiction and substance use disorders. Comparable to Anebulo in pursuing novel mechanisms for substance-related indications at an early clinical stage.

Direct peers

• Corcept Therapeutics: Specialty pharmaceutical company developing small-molecule receptor antagonists (cortisol/glucocorticoid receptor) for underserved indications, with a similar single-asset clinical-stage business model and orphan-drug commercial strategy that mirrors Anebulo's CB1 antagonist approach.

Others

• Emergent BioSolutions: Specialty biopharma developing medical countermeasures and acute-care therapeutics, including antidotes and treatments for toxic exposures. Comparable to Anebulo via the niche of acute antidote-style pharmaceuticals delivered in emergency settings.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/AnebuloP
• Instagraminstagram.com/Anebulopharmaceuticals
• LinkedInlinkedin.com/company/anebulo-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds6 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anebulo Pharmaceuticals